89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, reported its financial results for the quarter and full year ended December 31, 2021.
March 24, 2022
· 9 min read
